S'abonner navigation icon
FR
navigation icon menu icon S'abonner
navigation icon Accueil navigation icon Catalogue
icon language Langues navigation icon Menu
icon close
icon arrow

Rechercher

icon searchbar

Rechercher

Catalogue

icon close
icon close
icon close
icon language

Langues

icon close
background image
button download
icon share social
Category Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation by the US FDA for AFN-1252 and Completion of Dosing of AFN-1720 Phase 1 Trial
Lire
Lire

Affinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation by the US FDA for AFN-1252 and Completion of Dosing of AFN-1720 Phase 1 Trial

  • 4

    pages

  • English

  • Documents

  • 2013

Publié par
icon arrow

  • 4

    pages

  • English

  • Documents

  • 2013

Lire
Lire
icon

Description

Affinium Pharmaceuticals AnnouncesAffinium Pharmaceuticals Announces Qualified Infectious Disease Product (QIDP) Designation by the US FDA for AFN-1252 and Completion of Dosing of AFN-1720 Phase 1 Trial PR Newswire AUSTIN, Texas and TORONTO, November 12, 2013 Affinium Pharmaceuticals ("Affinium") announced today that the U.S.
Voir icon arrow
icon success

Ajouté à mes notifications

Vous serez informé des prochaines publications.